Curis (CRIS)
(Delayed Data from NSDQ)
$8.84 USD
-0.83 (-8.58%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $8.68 -0.16 (-1.81%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Curis, Inc. [CRIS]
Reports for Purchase
Showing records 181 - 200 ( 303 total )
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Debiopharm Initiates a Phase I/II Trial to Evaluate Debio 0932 in NSCLC
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Debiopharm Initiates a Phase I/II Trial to Evaluate Debio 0932 in NSCLC
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2Q12 Results; Erivedge Launch Encouraging, Pipeline Updates in 2H12
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Erivedge Starting to Hit Stride; Reiterate Buy and Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
CUDC-907 Preclinical Data Published in Clinical Cancer Research, Supports Phase I Trial
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
CUDC-907 Preclinical Data Published in Clinical Cancer Research, Supports Phase I Trial
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
We are placing Curis under review due to the departure of the covering analyst
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Signs of Erivedge Activity in Pancreatic Cancer
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
HIGHLIGHTS FROM THE 2012 ASCO MEETING - DAY 2This report contains brief updates on the following: ONTY, CRIS, SPPI, DNDN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.